GP2017: An Adalimumab Biosimilar

Heo, YA

Heo, YA (reprint author), Springer, Private Bag 65901, Auckland 0754, New Zealand.

BIODRUGS, 2018; 32 (6): 635

Abstract

GP2017 (adalimumab) is a biosimilar anti-TNF- antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索